Adamax vs P21
A side-by-side research comparison of Adamax and P21 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adamax | P21 |
|---|---|---|
| Full name | Adamax (Semax Analog Nootropic Peptide) | P21 (CNTF-Derived Tetrapeptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research peptide | Research compound |
| Mechanism | As an ACTH/melanocortin-derived peptide analog, it is proposed to elevate BDNF and other neurotrophic factors, modulate the dopaminergic and serotonergic systems, and provide neuroprotection, similar to but reportedly more potent and longer-acting than Semax. | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. |
| Molecular weight | ~ (short peptide) | ~450 Da |
| Half-life | Short (extended vs Semax) | 4-6 hours |
| Bioavailability | Intranasal or subcutaneous | Moderate (crosses BBB) |
| Typical dose | Low microgram-to-milligram range (research) | 50-100 mcg/kg |
| Frequency | 1-2x daily | Daily |
| Route | Intranasal or subcutaneous | Intranasal or Subcutaneous |
Adamax reported benefits
- Cognitive enhancement and focus
- Memory support
- Neuroprotection
- BDNF elevation (proposed)
- Mood support
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Related comparisons
Research and educational reference only. Not medical advice.